System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
基本信息
- 批准号:10375723
- 负责人:
- 金额:$ 46.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAffectAgonistAntibody ResponseAntigensAttenuatedAutomobile DrivingB-LymphocytesBiologicalCD4 Positive T LymphocytesCellsClinicalClinical TrialsCollaborationsDataData SetDevelopmentElderlyGene Expression ProfilingGlycoproteinsGoalsHerpes zoster diseaseHerpesvirus Type 3HumanImmune responseImmunityImmunologicsInnate Immune ResponseInvestigationLiposomesMalaria VaccinesMemoryMemory B-LymphocyteMolecularNamesNatural ImmunityPathway interactionsPeripheral Blood Mononuclear CellPlasmablastPopulationPublic HealthQS21RecombinantsResearchResearch PersonnelResolutionSaponinsSerumSubunit VaccinesSystemSystems AnalysisSystems BiologyT cell responseT-LymphocyteTLR4 geneTechnologyVaccinationVaccinesVirusWorkZoster Vaccineadaptive immune responseage groupbasebiological systemscytokinedata managementhuman very old age (85+)insightmetabolomicsnovel vaccinesresponsesingle cell technologyvaccine efficacy
项目摘要
The research proposed in years 6 and 7 of the Emory-HIPC will build on the considerable progress made
during the first 5 years in using systems based approaches to understand the molecular networks driving
innate and adaptive immune responses to vaccination. The major focus of the work planned in years 6
and 7 is to understand the immunological mechanisms by which the recently licensed subunit vaccine for
herpes zoster (HZ, shingles) induces highly efficacious protection against shingles. HZ which is caused by
the varicella zoster virus (VZV), affects several million people/year globally, and is a significant public
health concern for the elderly. An important recent development is the development of a new subunit HZ
vaccine, which contains the recombinant glycoprotein E subunit (“gE vaccine”), adjuvanted with AS01, a
liposome-based adjuvant system containing the TLR4 agonist MPL, and the saponin, QS21 (1-4). The gE
vaccine has recently been licensed for clinical use in subjects older than 50 years, under the trade name
Shingrix®. Remarkably, the efficacy of Shingrix® is high (91%) even in 70 year old vaccinees (1-4).
Although Shingrix® has revealed superior antibody responses and greater durability of CD4+ T cell
responses to the gE vaccine, a comprehensive assessment of immune responses to the gE vaccine is
lacking. This will be achieved in Aims 1 and 2, where we will analyze the innate and adaptive responses
to Shingrix®. Importantly we will analyze these results in the context of data generated from our previous
HIPC project on immune responses induced by the live attenuated zoster vaccine, Zostavax®.
Aim 1: Systems analysis of innate responses elicited by Shingrix® in 50-60 year old and >70 year old
subjects.
Aim 2: To analyze the adaptive immune response elicited by Shingrix® in 50-59 year old and >70-85
years old subjects.
埃默里重债穷国倡议第六年和第七年提出的研究将建立在已取得的重大进展的基础上
在使用基于系统的方法来理解分子网络驱动的头 5 年里
对疫苗接种的先天和适应性免疫反应。第六年计划工作重点
7是了解最近获得许可的亚单位疫苗的免疫学机制
带状疱疹(HZ,带状疱疹)可有效预防带状疱疹。 HZ 是由
水痘带状疱疹病毒 (VZV) 每年影响全球数百万人,是一种重要的公共疾病
关心老年人的健康。最近的一个重要进展是新亚基 HZ 的开发
疫苗,含有重组糖蛋白 E 亚基(“gE 疫苗”),并以 AS01 为佐剂,
基于脂质体的佐剂系统,含有 TLR4 激动剂 MPL 和皂苷 QS21 (1-4)。基因E
该疫苗最近已获准在 50 岁以上受试者中进行临床使用,商品名为
Shingrix®。值得注意的是,即使对于 70 岁的疫苗接种者 (1-4),Shingrix® 的功效也很高 (91%)。
尽管 Shingrix® 已展现出卓越的抗体反应和 CD4+ T 细胞的更高耐久性
对 gE 疫苗的反应,对 gE 疫苗免疫反应的全面评估是
缺乏。这将在目标 1 和 2 中实现,我们将分析先天反应和适应性反应
到 Shingrix®。重要的是,我们将在我们之前生成的数据的背景下分析这些结果
重债穷国项目关于由带状疱疹减毒活疫苗 Zostavax® 诱导的免疫反应。
目标 1:对 Shingrix® 在 50-60 岁和 >70 岁人群中引起的先天反应进行系统分析
科目。
目标 2:分析 Shingrix® 在 50-59 岁和 >70-85 岁人群中引发的适应性免疫反应
岁的科目。
项目成果
期刊论文数量(102)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.
- DOI:10.1002/hep.27761
- 发表时间:2015-06
- 期刊:
- 影响因子:13.5
- 作者:Thapa, Manoj;Chinnadurai, Raghavan;Velazquez, Victoria M.;Tedesco, Dana;Elrod, Elizabeth;Han, Jin-Hwan;Sharma, Prachi;Ibegbu, Chris;Gewirtz, Andrew;Anania, Frank;Pulendran, Bali;Suthar, Mehul S.;Grakoui, Arash
- 通讯作者:Grakoui, Arash
Zika Virus Infects Human Placental Macrophages.
- DOI:10.1016/j.chom.2016.05.015
- 发表时间:2016-07-13
- 期刊:
- 影响因子:30.3
- 作者:Quicke KM;Bowen JR;Johnson EL;McDonald CE;Ma H;O'Neal JT;Rajakumar A;Wrammert J;Rimawi BH;Pulendran B;Schinazi RF;Chakraborty R;Suthar MS
- 通讯作者:Suthar MS
Immunogenomics and systems biology of vaccines.
- DOI:10.1111/j.1600-065x.2010.00971.x
- 发表时间:2011-01
- 期刊:
- 影响因子:8.7
- 作者:Buonaguro L;Pulendran B
- 通讯作者:Pulendran B
Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV.
识别VZV,HSV和EBV之间保守的表位的广泛反应性人CD8 T细胞。
- DOI:10.1371/journal.ppat.1004008
- 发表时间:2014-03
- 期刊:
- 影响因子:6.7
- 作者:Chiu C;McCausland M;Sidney J;Duh FM;Rouphael N;Mehta A;Mulligan M;Carrington M;Wieland A;Sullivan NL;Weinberg A;Levin MJ;Pulendran B;Peters B;Sette A;Ahmed R
- 通讯作者:Ahmed R
Network-based modular latent structure analysis.
- DOI:10.1186/1471-2105-15-s13-s6
- 发表时间:2014
- 期刊:
- 影响因子:3
- 作者:Yu T;Bai Y
- 通讯作者:Bai Y
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rafi Ahmed其他文献
Rafi Ahmed的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rafi Ahmed', 18)}}的其他基金
System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
- 批准号:
10345981 - 财政年份:2021
- 资助金额:
$ 46.77万 - 项目类别:
System Biological Analyses of Adaptive Responses to vaccination
疫苗接种适应性反应的系统生物学分析
- 批准号:
10201503 - 财政年份:2020
- 资助金额:
$ 46.77万 - 项目类别:
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
利用 PD-1 的力学生物学进行癌症免疫治疗
- 批准号:
10174887 - 财政年份:2020
- 资助金额:
$ 46.77万 - 项目类别:
System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
- 批准号:
10056675 - 财政年份:2020
- 资助金额:
$ 46.77万 - 项目类别:
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
利用 PD-1 的力学生物学进行癌症免疫治疗
- 批准号:
10408747 - 财政年份:2020
- 资助金额:
$ 46.77万 - 项目类别:
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
利用 PD-1 的力学生物学进行癌症免疫治疗
- 批准号:
10524207 - 财政年份:2020
- 资助金额:
$ 46.77万 - 项目类别:
System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
- 批准号:
10201491 - 财政年份:2020
- 资助金额:
$ 46.77万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 46.77万 - 项目类别:














{{item.name}}会员




